Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
| ▸ | PYGL | P06737 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 3/20 | 0.33 |
| ▸ | PPARA | Q07869 | 3/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.32 |
| ▸ | THRA | P10827 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23980788 | 1.00 | KCNH2 (0.44) | KCNH2NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL24186460 | 0.86 | KCNH2 (0.40) | KCNH2NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL26516076 | 0.85 | KCNH2 (0.36) | KCNH2SMN1; SMN2MRGPRX4GRIN2B | |
| SCHEMBL29924274 | 0.85 | KCNH2 (0.40) | KCNH2NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL29149840 | 0.85 | KCNH2 (0.40) | KCNH2NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL25405457 | 0.82 | MAPT (0.40) | KCNH2 | |
| SCHEMBL30217471 | 0.82 | MAPT (0.40) | KCNH2 | |
| SCHEMBL29149966 | 0.80 | KCNH2 (0.43) | KCNH2NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL28964538 | 0.78 | GRM2 (0.33) | KCNH2NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL23980829 | 0.77 | NPC1 (0.36) | KCNH2NPC1HPGDRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4732838-A2 | PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTALLINE FORM OF GLP-1 RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2026-04-29 | — | — | EP | disclosed |
| EP-4725484-A2 | CRYSTALLINE FORM OF GLP-1 RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2026-04-15 | — | — | EP | disclosed |
| EP-4455140-B1 | CRYSTALLINE FORMS OF A GLP-1 RECEPTOR AGONIST AND PREPARATION METHODS THEREFOR | JIANGSU HENGRUI PHARMACEUTICALS CO LTD (CN) | 2026-04-01 | — | — | EP | disclosed |
| EP-4455141-B1 | PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTALLINE FORM OF A GLP-1 RECEPTOR AGONIST FOR THE TREATMENT OF DIABETES | JIANGSU HENGRUI PHARMACEUTICALS CO LTD (CN) | 2026-03-25 | — | — | EP | disclosed |
| EP-4706757-A2 | 2-(((2,3-DIHYDROBENZO[B][1,4]DIOXAN-5-YL)PIPERIDIN-1-YL)METHYL)-1-((OXETAN-2-YL)METHYL)-1H-BENZO[D]IMIDAZOLE-6-CARBOXYLIC ACID DERIVATIVES AND SIMILAR COMPOUNDS AS GLP-1 MODULATORS FOR THE TREATMENT OF DIABETES | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2026-03-11 | — | — | EP | disclosed |
| EP-4209490-B1 | 2-(((2,3-DIHYDROBENZO[B][1,4]DIOXAN-5-YL)PIPERIDIN-1-YL)METHYL)-1-((OXETAN-2-YL)METHYL)-1H-BENZO[D]IMIDAZOLE-6-CARBOXYLIC ACID DERIVATIVES AND SIMILAR COMPOUNDS AS GLP-1 MODULATORS FOR THE TREATMENT OF DIABETES | JIANGSU HENGRUI PHARMACEUTICALS CO LTD (CN) | 2026-01-28 | — | — | EP | disclosed |
| US-12473279-B2 | Fused imidazole derivative, preparation method therefor, and medical use thereof | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2025-11-18 | — | — | US | disclosed |
| US-12459937-B2 | Fused imidazole derivative, preparation method therefor, and medical use thereof | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2025-11-04 | — | — | US | disclosed |
| US-20250282773-A1 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2025-09-11 | — | — | US | disclosed |
| US-20250243195-A1 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2025-07-31 | — | — | US | disclosed |
| CN-118434730-A | Pharmaceutically acceptable salt and crystal form of GLP-1 receptor agonist and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-118401518-A | Crystalline form of GLP-1 receptor agonist and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2024-07-26 | — | — | CN | disclosed |
| US-20240246958-A1 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2024-07-25 | — | — | US | disclosed |
| US-20230322756-A1 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| EP-4209490-A1 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2023-07-12 | — | — | EP | disclosed |
| WO-2023116882-A1 | PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTALLINE FORM OF GLP-1 RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR | 江苏恒瑞医药股份有限公司 | 2023-06-29 | — | — | WO | disclosed |
| WO-2023116879-A1 | CRYSTALLINE FORM OF GLP-1 RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR | 江苏恒瑞医药股份有限公司 | 2023-06-29 | — | — | WO | disclosed |
| CN-115884969-A | Condensed imidazole derivative, preparation method and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2023-03-31 | — | — | CN | disclosed |
| EP-4143183-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| CN-115667250-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2023-01-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322756-A1 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | GLP1R, GIPR, VIP | KCNH2 1512/4885NPC1 1250/4885HPGD 674/4885 |
| US-12459937-B2 | Fused imidazole derivative, preparation method therefor, and medical use thereof | GLP1R, GIPR, VIP | KCNH2 1512/4885NPC1 1250/4885HPGD 674/4885 |
| US-20240246958-A1 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | GLP1R, GIPR, VIP | KCNH2 1512/4885NPC1 1250/4885HPGD 674/4885 |
| US-12473279-B2 | Fused imidazole derivative, preparation method therefor, and medical use thereof | GLP1R, GIPR, VIP | KCNH2 1512/4885NPC1 1250/4885HPGD 674/4885 |
| US-20250282773-A1 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | GLP1R, GIPR, VIP | KCNH2 1512/4885NPC1 1250/4885HPGD 674/4885 |
| US-20250243195-A1 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | GLP1R, GIPR, VIP | KCNH2 1512/4885NPC1 1250/4885HPGD 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.